Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

Rafei-Shamsabadi, David; Lehr, Saskia; Behrens, Max; Meiss, Frank

Rafei-Shamsabadi, David; Lehr, Saskia; Behrens, Max; Meiss, Frank.

Afiliación

Rafei-Shamsabadi D; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
Lehr S; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
Behrens M; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Zinkmattenstr. 6a, 79108 Freiburg, Germany.
Meiss F; Department of Dermatology and Venereology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.

Cancers (Basel) ; 14(3)2022 Jan 21.

Article en En | MEDLINE | ID: mdl-35158808

Palabras clave

Interleukin-2; PD-1 inhibitor; combination therapy; intralesional; metastatic melanoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google